Cosmo receives positive EMA CHMP Opinion recommending approval of Methylene Blue MMX for the visualization of colorectal lesions during colonoscopies
Cosmo Pharmaceuticals NV today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Methilthioninium Chloride Cosmo (Methylene Blue MMX), its drug for the visualization of colorectal lesions during colonoscopies.